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Monoclonal antibodya b s t r a c t
When analyzing large complex protein biopharmaceuticals, ion-pairing agents imparting low pH are
widely used as mobile phase additives to improve the chromatographic performance. However, one of
the most effective additives in RPLC and HILIC, trifluoroacetic acid (TFA), is known as a strong suppressor
of the MS signal and limits its use in hyphenated techniques. In this study, we evaluated a wide range of
acidic additives to find alternatives to TFA that provided comparable chromatographic performance and
improved MS sensitivity. It was observed that stronger acidic additives were required for intact level
analysis compared to subunit level analysis and that the additive nature had a larger impact on the
chromatographic performance in HILIC mode compared to RPLC. Therefore, four additives were identi-
fied as valuable alternatives to TFA in RPLC mode, namely, difluoroacetic acid (DFA), dichloroacetic acid
(DClAA), trichloroacetic acid (TClAA), and methanesulfonic acid (MSA). Only one of these additives
provided acceptable performance in HILIC mode, namely, TClAA.
After evaluation of the MS performance, TClAA was discarded due to the apparent loss of intensity in
both RPLC-MS and HILIC-MS mode. Together, these results demonstrate that for HILIC-MS analysis TFA
remains the gold standard additive. However, DFAwas found as promising alternative to TFA for RPLC-MS
analysis and could play an important role in the development of methods for the characterization of the
increasingly complex protein biopharmaceuticals.
© 2021 The Author(s). Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Sciences of Western Switzerland (ISPSO), School of Pharmaceutical Sciences, University of Geneva, CMU - Rue Michel
i).
ier B.V. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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Over the past decades, biopharmaceuticals, and among them,
monoclonal antibodies (mAbs), have emerged as an important class
of therapeutics [1,2]. Thanks to their ability to specifically target
antigens, mAb therapies experienced an explosive growth and have
become the reference treatment for many life-threatening diseases
[3]. MAbs are complex macromolecules of MW approximately
150 kDa that are produced in biological systems using recombinant
DNA technology. This complex manufacturing process can generate
thousands of possible variants of a given mAb product as a result of
chemical and enzymatic modifications introduced during the
expression, production and storage of mAbs [4]. Some of these
modifications can be critical for the safety and efficacy of the drug
product and are therefore known as critical quality attributes
(CQAs). To ensure the quality and safety of each therapeutic agent,
there is a need of state-of-the-art analytical strategies to monitor
the CQAs [5]. Among them, liquid chromatography coupled to mass
spectrometry (LC-MS) has become a key technique for the detailed
structural characterization of mAbs [6]. In this respect, two dena-
turing chromatographic techniques are generally applied and
coupled directly with MS, namely reversed phase liquid chroma-
tography (RPLC) and hydrophilic interaction chromatography
(HILIC). While solute retention in RPLC is controlled principally by
hydrophobic interactions [7], solute retention in HILIC is more
complex and involves a combination of hydrophilic partitioning,
hydrogen bonding, dipole-dipole and ionic interactions [8,9]. As a
result, and contrary to RPLC, HILIC conditions enable the separation
of glycoforms that are considered important CQAs of mAbs.
Therefore, these two approaches are highly complementary, since
their differences in retention mechanism result in differences in
elution order and selectivity [10].
However, the high-molecular weight of mAbs and their
numerous conformations make them challenging to characterize. A
number of limitations exists and require special consideration.
Strong secondary interactions between positively charged bio-
molecules and negatively charged residual silanols at the surface of
the stationary phase are one of the major concerns when analyzing
biomolecules [11]. Non-desirable interactions of proteins with the
stationary phase or with the HPLC instrumentation may occur
[11e13]. To prevent this, the choice of an appropriate stationary
phase material with wide pore size and the use of sufficiently high
column temperatures (generally 60e90 C) is crucial [14]. At high
temperatures, the mobile phase viscosity is reduced, diffusivity is
improved, and adsorption/desorption kinetics are accelerated [15].
However, caution must be taken to avoid potential thermal
degradation of proteins. In addition, the use of a bio-inert system
can be beneficial to further reduce unwanted adsorption during
analysis [14]. The large size of the mAbs also results in a slow
diffusivity and mass transfer of the analytes: severe band broad-
ening may be experienced, as well as peak tailing [16]. Together,
these phenomena negatively affect the chromatographic perfor-
mance. Fortunately, these effects can be limited by the addition of
acidic additives to the mobile phase [7]. By acting as ion-pairing
agents, acidic additives can form neutral ion-pairs with the basic
groups of the protein, namely histidine, lysine and arginine and
thereby enhance the hydrophobic character of the analyte [13]. This
will lead to better retention and improved peak shapes during
analysis. Furthermore, the use of strongly denaturing conditions
(i.e. acidic pH, high temperatures, organic solvents) greatly reduces
the amount of protein conformers and therefore results in sharper
andmore symmetrical peaks. In addition, the use of acidic additives2
can reduce the amount of secondary ionic interactions between the
protein and stationary phase by protonating negatively charged
silanol groups and neutralizing acidic amino acids (e.g., aspartic
acid, glutamic acid) [17]. As a result, peak broadening is minimized
[18].
When working in LC-MS conditions, an additive is expected to
provide good chromatographic performance, as well as sufficient
MS sensitivity. Currently, trifluoroacetic acid (TFA) is considered as
the gold standard mobile phase additive to enhance chromato-
graphic performance of protein biopharmaceuticals. Being a strong
acid (pKa ¼ 0.3), TFA is a very effective ion-pairing agent that
provides symmetrical and narrow peak shapes for proteins
analyzed in RPLC and HILIC. Unfortunately, TFA is also known as a
strong suppressor of the MS signal [18]. Ion-pairs involving TFA are
indeed hardly breakable and TFA prevents the ionisation of analytes
since only charged species are detected in MS conditions [19]. In
addition, TFA results in spray instabilities, due to the high con-
ductivity and high surface tension of the eluent further hampering
MS detection [18]. For these reasons, other additives have been
already investigated. Formic acid (FA, pKa ¼ 3.75), which is a
weaker ion-pairing agent than TFA, is often used because of its good
MS detection properties. However, the chromatographic perfor-
mance is reduced due to the weaker ion-pairing effect [20]. A
compromise between chromatographic performance and MS
sensitivity may also be found by mixing small amounts of FA and
TFA [21]. Other alternative mobile phase compositions have been
tested, such as perfluorinated acids, ammonium formate buffer or
more recently, difluoroacetic acid (DFA) and methanesulfonic acid
(MSA) [18,22e24].
In this study, we have expanded the range of possibilities for
choosing the appropriate mobile phase additive for mAb charac-
terization. We have attempted to find alternatives to TFA that can
provide excellent chromatographic performance without neglect-
ing the MS sensitivity. For this purpose, fourteen derivatives of
acetic acid were considered in addition to MSA. All these mobile
phase additives have a pKa in the range of 1.9 and 4.76, possess
from one to three halogen groups (i.e. chloro-, bromo-, iodo- or
trifluoro-) and their similar or derived structure from TFA renders
them interesting to investigate as alternative mobile phase modi-
fiers. The additive performance was first studied and compared at
the chromatographic level, in both RPLC and HILIC modes by using
a fluorescence detector (FLD). For this, different mAbs were
analyzed at both intact and subunit level. Then, volatility was
assessed for selected additives and finally the performance was
investigated in MS to evaluate their relevance in LC-MS.2. Experimental
2.1. Materials and reagents
Rituximab, trastuzumab, bevacizumab, daratumumab, inflix-
imab, pembrolizumab, cetuximab and pertuzumab were obtained
as European Union pharmaceutical-grade drug products from their
respective manufacturers. Water (art. W/0122/17) and acetonitrile
(art. A/0638/17) were UPLC-MS grade and purchased from Fisher
Scientific (Reinach, Switzerland). Trifluoroacetic acid (TFA, 99%,
art. 302031), formic acid (FA, 98%, art. 33015), acetic acid (AA,
99.7%, art. 695092), difluoroacetic acid (DFA, 98%, art. 142859),
dichloroacetic acid (DClAA, 99%, art. D54702), trichloroacetic acid
(TClAA, 99%, art. T6399), iodoacetic acid (IAA, 98%, art. I4386),
bromoacetic acid (BrAA, 99%, art. 17000), dibromoacetic acid
(DBrAA, 97%, art. 242357), tribromoacetic acid (TBrAA, 99%, art.
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base (99.8%, art. 93362) and dithiothreitol (DTT, art. 43815) were
obtained from Sigma-Aldrich (Buchs, Switzerland). MS-grade
difluoroacetic acid (Ionhance DFA, art. 720006578 EN) was ob-
tained from Waters (Milford, MA, USA). Immunoglobulin-
degrading enzyme of Streptococcus pyogenes (IdeS, FabRICATOR,
art. A0-FR1-250) was purchased from Genovis Inc. (Lund, Sweden).
2.2. Sample preparation
2-mL IdeS aliquots (67 U/mL) were initially prepared by recon-
stituting lyophilized IdeS enzyme in the appropriate volume of
water and stored at e 20 C (stable up to 6 months). 1 M DTT so-
lution and 100 mM TRIS buffer pH 7.5 (adjusted with HCl) were
freshly prepared before use. Intact sample was prepared by diluting
themAb product to 1mg/mLwithwater. Digested/reduced samples
were prepared according to the following procedure. MAb material
was diluted with water to 10 mg/mL in 10 ml and added to 10 mL of
100 mM TRIS buffer and 68 mL of water. 2-mL IdeS enzyme aliquot
was added and the resulting solution was incubated at 45 C for
45 min 10 mL of 1 M DTT solution was then added to the 90-mL
digested sample and incubated at 45 C for 45 min. Final DTT
concentration was 100 mM, final TRIS buffer concentration was
10 mM and final protein concentration was 1 mg/mL. The 100-mL
samples were then transferred to HPLC vials for the analysis. As
result of protein IdeS digestion and DTT reduction, Fd’, LC and sFc
fragments were obtained. The prepared samples were analyzed
within 2e3 days if stored at 4 C.
2.3. Chromatographic media
2.3.1. Instrumentation
LC analyses were performed on an ACQUITY UPLC™ H-Class
system (Waters, Milford, MA, USA), equipped with an auto-sampler
including a 10-mL flow-through-needle injector, a quaternary sol-
vent delivery pump and a fluorescence detector (excitation at
280 nm, emission at 360 nm, 5 Hz, 0.2-s time constant, 2-mL de-
tector flow-cell). LC-MS analyses were performed on an ultrahigh
performance liquid chromatography (UHPLC) system (ACQUITY
UPLC, Waters, Milford, MA, USA) coupled to an electrospray time-
of-flight mass spectrometer (Xevo Q-ToF, Waters, Milford, MA,
USA). The UHPLC system was equipped with a binary solvent de-
livery pump, a 1 mL fixed loop autosampler and a FLR detector
(excitation at 280 nm, emission at 340 nm, 10 Hz). The mass
spectrometer was operated in ESI þ mode in the range 500e5500
m/z with a scan time of 1.0 s. Source temperature was 150 C and
capillary and extraction cone voltages were set 3 kV and 4 V,
respectively. Desolvation temperature and gas flow were 500 C
and 1000 L/h, respectively. The system was calibrated by using
sodium iodide (200 pg/mL in 50/50 ACN/water with 0.1% FA). Data
acquisition and instrument control were performed by Empower
Pro 3 software (Waters) or MassLynx 4.1 software (Waters), ac-
cording to the used instrument, namely the UPLC™ H-Class system
or the UPLC™- Xevo™ Q-ToF system. LC system lines and syringes
were primed before use to ensure the elimination of possible air
bubbles in the system. Columns were equilibrated for at least 10
column volumes, by using the solvent composition that was used at
the beginning of the gradient elution program. In HILIC, 85:15 ACN/
H2O and 40:60 ACN/H2O were used as weak and strong wash,
respectively. In RPLC, both washes were 50:50 ACN/H2O.
2.3.2. RPLC and HILIC columns
In RPLC mode, the BioResolve RP mAb Polyphenyl column
(2.7 mm, 150 mm  2.1 mm, 450 Å) from Waters (art. 186009017,
Milford, MA, USA) and the Halo C4 column (2.7 mm,3
150 mm  2.1 mm, 1000 Å) columns from Advanced Materials
Technology (art. 92712-714, Wilmington, DE, USA) were used. In
HILIC mode, the ACQUITY UPLC Glycoprotein Amide column
(1.7 mm, 150 mm  2.1 mm, 300 Å) from Waters (art. 186007963,
Milford, MA, USA) was used. After use, RPLC and HILIC columns
were rinsed and stored in 100% acetonitrile for the best column
lifetime.
2.4. Chromatographic conditions
In RPLC and HILIC, the flow rate was set at 0.4 mL/min and the
column temperature was set at 80 C. MAbs were analyzed at both
intact and subunit level. All mAb samples were concentrated to
1 mg/mL and injection volume was 1 mL. Mobile phase consisted of
additive in water (A) and additive in acetonitrile (B). All experi-
ments were performed in duplicate and identical chromatograms
(perfectly overlaid without any shift in retention time or change in
the peak shape) were always obtained between the two successive
runs. Fluorescence detection was used to avoid additional adsorp-
tion in the detector, and FL-chromatograms were acquired at
lexcitation ¼ 280 nm and lemission ¼ 360 nm.
2.4.1. RPLC conditions
In RPLC, the conditions included a gradient of 14%B in 12 min,
followed by a 1-min washing step at 70%B and a 4.5-min re-
equilibration at the initial conditions. Gradient conditions were
optimised during preliminary studies depending on the additive
used as mobile phase modifier. They consisted of 26e40%B for MSA
and IAA, 30e44%B for TBrAA and TClAA, 27e41%B for DBrAA and
DClAA, 25e39%B for BrAA and DFA, 23e37%B for FA and 28e42%B
for TFA. Optimization was not achieved using AA: the tested
gradient was 20e90%B followed by a 1-min washing step at 90%B.
2.4.2. HILIC conditions
In HILIC, the conditions began by a 0.2-min gradient ramp from
85%B to the initial conditions to avoid peak distortion caused by the
high eluotropic strength of the aqueous sample. This fast gradient
ramp was followed by a gradient of 8%B in 12 min, then by a 1-min
washing step at 15%B and a 10-min re-equilibration at 85%B.
Gradient conditions were optimised during preliminary studies
depending on the additive used in themobile phase. They consisted
of 61-53%B forMSA, 71-63%B for TClAA and TFA, 69-61%B for DBrAA
and DClAA, 60-52%B for BrAA, 66-58%B for DFA and 53-45%B for FA.
2.4.3. LC-MS conditions
For RPLC-MS analyses, 1 mL of 1 mg/mL sample was injected in
partial loop mode (2-mL fixed loop). For HILIC-MS analyses, 1 mL of
1 mg/mL sample was injected in full loop mode (1-mL fixed loop)
and chromatographic conditions were further optimised, consist-
ing in 73-65%B for both TFA and TClAA.
2.5. Volatility assessment
Eluent volatility was assessed by low-temperature evaporative
light-scattering detection (LT- ELSD). No chromatographic column
was used. The pump of the ACQUITY UPLC™ H-Class system was
used to pump themixture of mobile phase A (additive inwater) and
mobile phase B (additive in acetonitrile) and was directly coupled
to a SEDEX LT-ELSD Model 90LT (SEDERE, France). A negative
control without additive, and a positive control with 0.1% phos-
phoric acid, were acquired to have reference values of a volatile and
a non-volatile mobile phase, respectively. The ELSD was set as
follows; gain ¼ 8, gas pressure ¼ 3.5 bar, evaporative tube
temperature ¼ 40 C, acquisition rate ¼ 10 Hz. The flow rate was
0.4 mL/min with a gradient of 5e95% B in 20 min. Between each
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H2O. If needed, a cleaning at 90 C was performed to remove po-
tential non-volatile compounds from the ELSD.
3. Results and discussions
3.1. Selection of suitable additives
With the aim to find alternative mobile phase additives
providing suitable chromatographic performance and acceptable
MS sensitivity compared to TFA, fourteen acidic compounds were
evaluated in this study, namely FA, AA, MFA, DFA, ClAA, DClAA,
TClAA, BrAA, DBrAA, TBrAA, IAA, BrDClAA, ClDBrAA, and MSA. A
complete list of the investigated additives is reported in Table 1,
together with information on their chemical characteristics,
including among others density, purity grade, state at room tem-
perature, pKa, and pH when prepared at a concentration of 0.1% in
water. In addition, safety information and price for commercial
available formats have been included for sake of completeness.
Already based on the information reported in Table 1, a first se-
lection was made and some additives were discarded from further
investigation. First, based on the safety information, ClAA was
removed because of its acute toxicity (in particular for the hazard
statement H330: fatal if inhaled). Then, ClDBrAA, BrDClAA, and
MFA were discarded, since they cost more than 100 USD for less
than 1 g of product and thus were not economically competitive on
the basis of the amount of acid required for the preparation of the
mobile phases. In addition, MFA was very difficult to handle due to
its melting point (mp ¼ 35 C, gel at room temperature). Therefore,
from the 14 additives, only 10 were considered suitable for further
investigation. It is worth highlighting that besides removing some
additives, a new MS-grade format of DFA was commercialized
while this work was being conducted. Based on preliminary tests,
the DFA purity grade showed to have a potential impact on peak
shape and above all MS sensitivity, as reported in Fig. 1 for the
analysis of trastuzumab in RPLC mode performed at intact and
subunit level. For this reason, the LC-grade DFA was substituted for
the MS-grade DFA for subsequent analyses.
3.2. Selection of a suitable RPLC column
In the last few years, there has been a significant number of
advances in reversed phase chromatographic columns for protein
analysis. First, it has been demonstrated that RPLC columns packed
with superficially porous particles (SPP) have the most advanta-
geousmorphology for the separation of largemolecules, due in part
to their smaller diffusion coefficients and the reduced solute
diffusion distance involved [25]. For this reason, the two RPLC
columns selected in this work, namely, the Halo C4 and Bioresolve
RP mAb polyphenyl are packed with SPP of 2.7 mm (rho value of
0.70). Next, the pore size has to be sufficiently large to accommo-
date large protein species (up to 150 kDa). Therefore, the two
selected stationary phases have wide pore sizes of 1000 Å and
450 Å, respectively [26]. Third, these two columns have good
thermal stability, and temperatures in the range 80e90 C can be
successfully used to achieve suitable protein recovery [16]. Last, the
only important difference between these two columns is the
chemistry. As described elsewhere, the Bioresolve RP mAb poly-
phenyl is based on a high coverage phenyl bonding [27]. Due to its
unique surface chemistry and large steric hindrance, this material
limits silanol interactions by extensively masking the base silica
particle, which is not the case of the Halo C4. This behaviour can be
observed in Fig. 2, showing the analysis of intact and digested/
reduced trastuzumab on the two columns using three different
mobile phase additives (1% FA, 0.1% DFA and 0.1% TFA). As expected,4
the observed differences between the two columns were minor or
even negligible when adding 0.1% TFA to the mobile phase (blue
traces on Fig. 2). This behaviour can be explained by the fact that
TFA is a relatively strong ion-pairing reagent, able to mask most of
the positive charges at the surface of the proteins, avoiding ionic
interaction with residual silanols. On the other hand, when using
0.1% DFA, the chromatographic profiles (yellow traces on Fig. 2)
were similar for the digested/reduced trastuzumab sample, but
some differences can be observed at the intact level between the
two columns. This was obviously attributed to the lower acidity of
DFA vs. TFA and the fact that it was less able to create ion-pairs.
Therefore, the presence and accessibility to residual silanols
become more challenging to overcome. This was particularly crit-
ical with intact mAbs (presence of a non-negligible number of
positive charges that were not adequately masked), and not with
mAb subunits of 25 kDa. In this case, the twominor variants eluting
after the main peak were lost in the tail of the main isoform on the
Halo C4 column. Last but not least, when using 1% FA as mobile
phase additive (red traces on Fig. 2), the differences between the
two columns became obvious irrespective of the sample being
analyzed (intact and digested/reduced mAb). Due to the weaker
acidity of formic acid, the advantage of the Bioresolve RP mAb
polyphenyl over the Halo C4 is clearly highlighted. However, the
performance achieved with 1% FA was reduced compared to the
two other additives, in particular for the intact mAb product.
Finally, to achieve the best performance with a wide range of
additives, the Bioresolve RP mAb polyphenyl was selected for the
rest of the study. Indeed, this stationary phase has the ability to
limit ionic interactions between the positively charged proteins and
the negatively charged silanols at the surface of the base particles,
thanks to its coverage phenyl bonding with peculiar steric hin-
drance limiting the access to the silanols, as already reported
elsewhere [27,28].
3.3. Preliminary results with selected additives
First, some experiments were carried out with both intact
trastuzumab and digested/reduced trastuzumab samples in the
RPLC (Bioresolve RP mAb polyphenyl) and HILIC (Glycoprotein BEH
Amide) modes using the additives selected in Section 3.1. For this
part of the work, the gradient conditions (initial and final compo-
sitions) were adjusted to have a suitable retention in all cases.
Among the selected additives, three of them were rapidly dis-
carded, namely 0.1% AA, 0.1% IAA and 0.1% TBrAA. With 0.1% AA, no
peak was observed for the intact trastuzumab and digested/
reduced trastuzumab samples both in RPLC and HILIC conditions
using the generic conditions (data not shown). AA is the weakest
acid of the list (pKa of 4.76) and probably has a too high pH to
suppress sufficiently the ionisation of silanols or is not able to
create sufficiently strong ion-pairs with proteins, leading to very
strong peak distortion and adsorption of the mAb at the surface of
the column. Next, the performance achieved with 0.1% IAA and
TBrAA for digested/reduced trastuzumab in RPLC mode were re-
ported in Fig. S1. As shown, the sensitivity was very low using
fluorescence detection (only 1 EU) in comparison with other ad-
ditives. In addition, only one peak was observed with 0.1%TBrAA,
and the three peaks observed with 0.1% IAA have very uncommon
shapes compared to what was observed with the sample in Fig. 2.
TBrAA is a relatively strong acid (pKa of 0.72), while the IAA is less
acidic (pKa of 3.18). However, these two acids have strong steric
hindrance due to the presence of three bromide or one iodide
atoms. Due to the non-negligible size of these atoms, it is highly
probable that these two acidic additives are not able to create
sufficiently strong ion-pairs with the proteins. Therefore, similarly
towhat happenedwith AA, the performance is unacceptable: peaks
Table 1
List and properties of investigated additives.











formic acid (FA) Sigma-
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2.87 ClCH2CO2H 94.49 solid 1.58 MS-
grade
Danger






1.26 2.18 Cl2CHCO2H 128.94 liquid 1.563 MS-
grade
Danger














2.90 2.48 BrCH2CO2H 138.948 solid 1.934 MS-
grade
Danger













0.72 2.08 CBr3CO2H 296.74 solid 3.098 MS-
grade
Danger
iodoacetic acid (IAA) Sigma-
Aldrich















0.13 ClCHBr2CO2H 252.29 liquid 2.684 MS-
grade
Danger
(continued on next page)
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Table 1 (continued )















-1.90 2.04 CH3SO3H 96.11 liquid 1.481 MS-
grade
Danger
Fig. 1. Effect of DFA grade on peak shape and sensitivity. RPLC chromatograms of
trastuzumab at intact (i and ii) and subunit (iii and iv) level. Analyses were performed
with LC-grade DFA (i and iii) and MS-grade DFA (ii and iv) by using the optimised
conditions described in Section 2.4.1. Peaks have been labelled with the corresponding
subunit name.
Fig. 2. Effect of RPLC columns on peak shape and sensitivity. RPLC chromatograms of
intact (AeC) and digested and reduced (BeD) trastuzumab obtained by using 0.1% TFA,
0.1% DFA and 1% FA (in blue, yellow and red, respectively) in the mobile phases.
Separation was performed on a BioResolve column (AeB) or a Halo C4 column (CeD)
by using the optimised conditions described in Section 2.4.1. Peaks have been labelled
with the corresponding subunit name. (For interpretation of the references to colour in
this figure legend, the reader is referred to the Web version of this article.)
H. Lardeux, B.L. Duivelshof, O. Colas et al. Analytica Chimica Acta 1156 (2021) 338347
6
are distorted or not eluted and adsorption is non-negligible.
The remaining eight additives were then tested at a concen-
tration of 0.1%, and FA was also evaluated at 1%. The corresponding
results obtained in RPLC and HILIC for intact trastuzumab and
digested/reduced trastuzumab samples are provided in Fig. 3. As
expected, the additive nature has a stronger impact on the intact
mAb (150 kDa) vs. the digested/reduced mAb (25 kDa fragments).
This is due to the fact that there are more positive charges to mask
through ion pairing, generating peak tailing effect for the largest
protein species. In addition, the diffusion coefficients of larger
species are smaller, leading to extra peak broadening.
In RPLC conditions (Fig. 3A and C), theworst additivewas clearly
0.1% FA, followed by 1% FA and 0.1% BrAA, whatever the sample.
Table 2 shows the retention times, widths, and asymmetries of the
last eluted peak (Fd species) as well as the selectivity between the
first two peaks (sFc and LC species). As reported, it is clear that
asymmetries were particularly unacceptable with FA (8.96 with
0.1% FA and 4.37 with 1% FA), while the peak observed with 0.1%
BrAA was particularly broad (45% broader than with 0.1% FA and
165% broader than with 0.1% TFA). The performance obtained with
the remaining six additives (i.e. MSA, TClAA, DClAA, DBrAA, DFA
and TFA) were however comparable in terms of peak width at half
height (between 0.0438 and 0.0586min) and quite close in terms of
asymmetry (between 1.27 and 2.13), even if some differences are
still observable in terms of selectivity (between 1.09 and 1.68).
In terms of sensitivity, considerable differences were also
observed between DClAA and DBrAA. The observed differences in
sensitivity could be attributed to the larger size of the bromide ions
compared to the chloride ions. Thus, based on the potential steric
hindrance of the two larger bromide groups and the lower elec-
tronegativity of Bromine, the use of DClAA would be better.
Besides the peak shapes, monitoring the selectivity is also
important to evaluate the quality of an additive. For this reason, the
selectivity between sFc and LC species was reported in Table 2, and
Fig. 4 shows the zoomed chromatograms for the six different ad-
ditives under RPLC conditions. As shown in Table 2, selectivity
between the first two main subunit peaks in Fig. 3C was between
1.09 and 1.68. This relatively large modification of selectivity shows
that the nature of the mobile phase additive has an impact on it and
can be used duringmethod development to tune selectivity. Among
all the tested additives, TClAA was the one providing the lowest
selectivity between these two subunits (a ¼ 1.09), while MSA
provides the largest separation (a ¼ 1.68). This difference in
selectivity between additives is visually observed in Fig. 4. In
addition, Fig. 4 also highlights the differences in separation quality
for the minor variants. From this figure, it is clear that all the minor
peaks eluting between the main subunit species are better resolved
with DFA, TFA, DClAA and MSA, rather than TClAA and FA. Based on
the peak shapes, retention and selectivity, several additives can be
successfully used for the RPLC analysis of biopharmaceutical
products. Even if TFA and FA remain the most widely used, it could
be interesting to evaluate several alternatives such as MSA, TClAA,
Fig. 3. Additive influence on peak shapes in RPLC and HILIC. RPLC (AeC) and HILIC (BeD) chromatograms of trastuzumab at intact (AeB) and subunit (CeD) level obtained by using
the optimised conditions described in Section 2.4. Peaks have been labelled with the corresponding subunit name.
Table 2
Chromatographic parameters of trastuzumab analyzed at intact andmiddle-up level
by HILIC and RPLC. Chromatographic conditions as from Fig. 3 tr; retention time
(min), w50%: peak width at half height, As: asymmetry factor @10, n.a. stands for not
applicable, a: selectivity (defined as the ability of the method to separate two
adjacent analytes from each other; it is calculated as: a ¼ k2/k1, where k1 and k2 are
the retention factors, k, of the first and second peaks of a peak pair, while k is
calculated as: k ¼ (tr e t0)/t0, where tr is the retention time of the peak of interest,





tr w50% As a tr w50% As a
0.1% MSA 7.190 0.0531 1.27 1.68 3.373 0.0533 2.39 1.21
0.1% TClAA 7.345 0.0586 1.42 1.09 3.276 0.0883 0.91 1.34
0.1% DClAA 7.118 0.0512 1.97 1.31 3.984 0.1996 2.56 1.33
0.1% DBrAA 7.335 0.0438 1.74 1.23 4.593 0.1657 1.91 1.32
0.1% BrAA 6.661 0.1478 0.98 1.57 4.111 n.a. n.a. n.a.
1% FA 7.938 0.0914 4.37 1.45 2.165 n.a. n.a. 1.03
0.1% FA 7.830 0.1015 8.96 1.42 3.550 n.a. n.a. n.a.
0.1% DFA 6.966 0.0520 2.13 1.53 3.116 0.1100 2.24 1.26
0.1% TFA 7.003 0.0556 1.45 1.33 3.389 0.0887 0.88 1.35
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In HILIC conditions (Fig. 3B and D), the conclusions are consid-
erably different since only a very limited number of additives
provided suitable chromatograms. This means that HILIC is more
sensitive to ion-pairing than RPLC. Generally, for intact mAbs, the
peaks observed in HILIC are broad, since the different glycoforms
are only partially resolved, as already reported elsewhere [10]. In7
Figs. 3B and 0.1% MSA, TFA and TClAA provided broad, but
acceptable peak shapes for the analysis of intact mAb under HILIC
conditions. It is important to notice that these three additives are
themost acidic ones (lowest pKa values between 1.26 and 1.48), and
are probably able to create the strongest ion-pairs or potentially
provide more suppression of silanol group ionisation. On the con-
trary, peaks were very broad and distorted with 0.1% DClAA, DBrAA
and DFA, which have intermediate pKa values between 1.26 and
1.48. Finally, the performance became totally unacceptable with
0.1% BrAA and FA, corresponding to the weakest acid (pKa values
between 2.9 and 3.75). The use of 1% FA is a special case since the
retention was strongly reduced compared to the other additives
and peak shape was more symmetrical. This behaviour was due to
the modification of the mobile phase ionic strength (corresponding
to approx. 200 mM FA), strongly reducing ion exchange mechanism
under HILIC conditions. In the end, it appears that the peak shapes
in HILIC are almost exclusively governed by the acidity of the ad-
ditive. Increasing the amount of additive in themobile phase can be
a good solution to improve chromatographic peak shape, but this
will hamper MS detectability and selectivity can be strongly
reduced, as shown in Fig. 3B. Strictly similar conclusions can be
drawn for subunit analysis, as shown in Fig. 3D. Again, there is a
need to have a highly acidic additive (0.1% MSA, TFA or TClAA) to
obtain suitable peak shapes in HILIC. Table 2 shows the peak widths
and asymmetry of the first eluted peak (Fd subunit), but only for a
very limited number of additives offering acceptable peak shapes.
As shown, peak widths are much broader (2 to 3-fold) than the
ones observed in RPLC and asymmetries are also close to 2 or even
Fig. 4. Zoom on RPLC chromatograms of digested and reduced trastuzumab using selected additives. Based on Fig. 3C. Peaks have been labelled with the corresponding subunit
name.
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was also calculated and reported in Table 2, by using a value higher
than 1.1 as acceptable criterion of goodness. As reported, selectivity
was almost similar whichever additive was used (a ¼ 1.26e1.33),
except for the 1% FA, where the selectivity becomes very low
(a ¼ 1.03).
When analysing subunits of trastuzumab, several glycoforms
can be separated on the sFc peak (last eluted peak). Therefore, we
have also investigated the separation quality for the glycoforms by
zooming in on the HILIC chromatograms obtained with the three
most promising additives (0.1% MSA, TFA and TClAA). As shown in
Fig. S2, the separation of various glycoforms can be achieved with
0.1% TFA (reference conditions). When switching to 0.1% TClAA, a
lower number of glycoforms was separated. Finally, with MSA, a
strong reduction of selectivity was observed for the glycoforms and
all the glycoforms eluted as two main species. Based on these re-
sults, and despite the reduction of selectivity between glycoforms
in some cases, three additives have the potential to be used in HILIC,
namely 0.1% MSA, TFA and TClAA.3.4. Application to wide range of monoclonal antibodies
After evaluating the chromatographic performance of the 11
different additives for the analysis of trastuzumab at intact and
subunit level, six additives were selected for RPLC and three addi-
tives for HILIC mode. To further evaluate the performance of these
selected additives, a wide range of mAbs (i.e., rituximab, trastuzu-
mab, bevacizumab, daratumumab, infliximab, pembrolizumab,
cetuximab, pertuzumab) was analyzed in RPLC and HILIC modes at
both intact and subunit levels. By using a specific gradient for each
additive, but the same gradient for all analytes, a clear comparison
could be made across the different mAbs.
In RPLC conditions, consistent results were obtained for the
eight differentmAbs at the intact level (Fig. S3), when using five out
of the six additives (i.e., TFA, TClAA, MSA, DFA and DClAA). Only
when using 1% FA as mobile phase additive, substantial peak tailing
was observed for all eight mAb products, causing poor overall
chromatographic performance. This again, highlights the8
importance of using a strong additive to mask all the protein pos-
itive charges when analysing mAbs at the intact protein level. Fig. 5
displays the corresponding chromatograms obtained after diges-
tion and reduction of the eight mAbs. A similar trend is visible at
the subunit level, where the performance of TFA, TClAA, MSA, DFA
and DClAA was comparable in terms of peak shape across the
subunits of eachmAb. For 1% FA (Fig. 5F), peak tailing hampered the
chromatographic performance, but to a lesser extent than at the
intact protein level.
Besides evaluating the effect of each additive on peak shapes, we
also monitored the influence of the additives on the selectivity.
From the preliminary results based on trastuzumab, discussed in
section 3.3, TClAA was considered to have the worst selectivity. As
illustrated in Fig. 5B, this limited selectivity can be problematic
when analysing multiple mAbs such as, rituximab, pembrolizumab
and pertuzumab, where the sFc and LC are closely eluting. This
problem could be easily overcome by switching to different addi-
tives, such as MSA, TFA, DFA and DClAA, where an improved
selectivity is provided, while maintaining an acceptable peak
shape. This effect demonstrates that the use of multiple additives
offering various selectivities can be a valuable tool to complement
an analysis strategy or to provide valuable alternatives to the use of
TFA.
To obtain acceptable peak shapes in HILIC conditions, we only
performed subunits analysis of the eight different mAbs using the
most acidic additives (i.e., TFA, TClAA andMSA). As can be observed
in Fig. 6A and B, TFA and TClAA provide highly comparable results
in terms of peak shape and selectivity. This is consistent with the
results obtained in the preliminary tests with trastuzumab, where
only minor differences in selectivity were observed between the
additives and a clear separation was found between the Fd and LC
subunits (Table 2). However, for rituximab, infliximab and pem-
brolizumab, the Fd and LC subunits co-eluted when TFA or TClAA
(Fig. 6A and B) were used as mobile phase additive. Surprisingly,
when using MSA (Fig. 6C) the separation efficiency improved, and
the Fd and LC species of rituximab, infliximab and pembrolizumab
could be separated. This indicates that the selectivity of MSA, in
HILIC conditions, is better than TClAA and TFAwhen separating the
Fig. 5. RPLC analyses performed at middle-up level using selected additives. RPLC chromatographic profiles of rituximab (i), trastuzumab (ii), bevacizumab (iii), daratumumab (iv),
infliximab (v), pembrolizumab (vi), cetuximab (vii), pertuzumab (viii) obtained by using the optimised conditions described in Section 2.4.1. Peaks have been labelled with the
corresponding subunit name.
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Fig. 6. HILIC analyses performed at middle-up using selected additives. HILIC chromatographic profiles of rituximab (i), trastuzumab (ii), bevacizumab (iii), daratumumab (iv),
infliximab (v), pembrolizumab (vi), cetuximab (vii), pertuzumab (viii) obtained by using the optimised conditions described in Section 2.4.2. Peaks have been labelled with the
corresponding subunit name.
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focusing only on the sFc subunit bearing the different glycoforms,
better selectivity was obtained when using TFA or TClAA, compared
to MSA.
This can partially be explained by the loss of retention observed
for the sFc subunits of each mAb when being analyzed with MSA
(Fig. 6C). A clear trend is visible when comparing the retention
times of the sFc subunits of the first mAb, rituximab (Fig. 6 i.), with
the retention times of the sFc subunits of the last analyzed mAb,
pertuzumab (Fig. 6 viii.), across the three tested additives. For TFA
(Fig. 6A) and TClAA (Fig. 6B), it is observed that the main sFc gly-
coforms of rituximab and pertuzumab elute at approximately the
same retention times. When performing a similar comparison for
MSA (Fig. 6C), a substantial decrease in retention was observed for
the sFc subunits of pertuzumab compared to the first injected sFc
subunits of rituximab. By including the other analyzed mAbs in the
comparison, a gradual decrease in retention was observed over the
course of the eight injections and suggests that the exposure of the
HILIC column to MSA leads to rapid alteration of the stationary
phase material. To confirm the detrimental effects of MSA on the
retention capacity of the HILIC column, we conducted a series of
experiments analysing trastuzumab subunits (using reference
conditions) after exposing the column material to 16 injections
using TClAA followed by 16 injections using MSA. As shown in
Fig. S4, the retention capacity of the column was sustained after
exposure to TClAA, but largely reduced after exposure to MSA. It is
expected that due to the strong acidic character of MSA, the addi-
tive is irreversibly adsorbed onto the stationary phase material,
thus lowering the amount of possible hydrophilic interactions. This
effect could lead to the observed reduction in retention of the mAb
subunits when using MSA.10Based on the presented results, four additives (i.e., MSA, TClAA,
DFA and DClAA) provided comparable peak shapes to TFA and
therefore could be considered as valuable alternatives under RPLC
conditions. In HILIC conditions, only TClAA has the potential to be
used as alternative to TFA due to the detrimental effects of MSA on
the retention of the mAb subunits. It is worth mentioning that,
small differences were observed in selectivity among the different
additives which could be used during method development.
However, the chromatographic performance (e.g., peak width and
asymmetry) of each additive can be considered more important,
due to the many possibilities to further increase the selectivity such
as the use of multi-isocratic gradients or application of negative
gradient slopemethods [29,30]. In addition, theMS compatibility of
a given additive plays an important role during method
development.
3.5. Hyphenation to mass spectrometry
From the 14 mobile phase additives initially selected for this
study, only five proved to have the potential for being valuable
alternatives to TFA in terms of chromatographic performance,
namely FA, DFA, DClAA, TClAA andMSA.With the aim to investigate
the possibility of using them for LC-MS applications, the volatility of
mobile phases prepared with the aforementioned additives was
assessed by low-temperature evaporative light-scattering detec-
tion (LT-ELSD). No chromatographic column was used for this test.
Apart from 0.1% MSA, all mobile phases demonstrated to be volatile
and therefore suitable for MS analysis. Based on these results, MSA
was discarded from further investigations. LC-MS performance of
the remaining 4 mobile phase additives were assessed by LC-MS
using a Quadrupole-Time of Flight (Q-ToF) MS detector and IdeS
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sentative mAbs. It is worth mentioning that cetuximab is a
particular mAb containing 2 conserved N-glycosylation sites
located on the heavy chains that after digestion and reduction are
present on the Fd’ and sFc subunits. For HILIC-MS experiments,
mobile phases containing 0.1% TFA and 0.1% TClAA were tested,
while for RPLC-MS, mobile phases containing 1% FA, 0.1% TFA, 0.1%
DFA, 0.1% DClAA and 0.1% TClAA were taken into consideration.
Fig. 7 shows the observed MS intensities reported as signal to noise
(S/N) ratio, evaluated on total ion chromatograms (TICs) of trastu-
zumab Fd’ and cetuximab LC subunits and also expressed as counts
per seconds (cps) S/N of the most abundant charge state of each
subunit. For sake of comprehensiveness, representative TICs of
digested and reduced trastuzumab acquired in RPLC and HILIC
modes are reported in Fig. 8 and Fig. 9, respectively, together with
the associated m/z spectra. As evidenced by the S/N histograms
(Fig. 7), 0.1% TClAA had the worst impact on the MS sensitivity in
both HILIC and RPLC modes. In RPLC mode (Fig. 8), despite the clear
improvement in chromatographic performance when using 0.1%
TClAA in comparison to 1% FA, MS sensitivity suffered of an average
intensity loss of 91% in cps S/N when passing from 1% FA to 0.1%
TClAA mobile phases. Similarly, in HILIC mode (Fig. 9), despite the
fact that chromatographic performance was comparable, MS
sensitivity results were showed an average intensity loss of 88% in
cps S/N when passing from 0.1% TFA to 0.1% TClAA mobile phases.
Based on these observations, 0.1% TFA remains the gold standard
additive for HILIC-MS analysis and the sought after MS signal
improvement should be realized via other strategies (e.g., by mix-
ing small amounts of FA and TFA, as already reported elsewhere)
[21]. On the other hand, for RPLC-MS analyses, interesting alter-
natives to 0.1% TFA were represented by 0.1% DFA, able to increase
the MS sensitivity with an average gain of 50% in terms of cps S/N
while keeping optimal chromatographic performance, and by 1% FA
that was able to increase the sensitivity of a 68% in terms of cps S/NFig. 7. Mass spectrometric S/N ratio of trastuzumab Fd (grey) and cetuximab LC (blue) su
additives. S/N ratio evaluated on total ion chromatograms (TIC) and on the highest charge s
interpretation of the references to colour in this figure legend, the reader is referred to the
11but at the expense of reduced chromatographic performance.4. Conclusions
To expand the range of mobile phase additives that can be used
for the characterization of protein biopharmaceuticals, we
compared a wide variety of acidic additives as ion-pairing agents in
RPLC- and HILIC-MS analysis. The additives were compared to TFA,
which is considered as the gold standard additive for enhancing the
chromatographic performance of protein biopharmaceuticals, but
is hampered by the strong ion suppressing effects in MS detection.
It was demonstrated that to obtain acceptable chromatographic
performance, stronger additives (e.g., MSA, TClAA, DClAA and DFA)
were required at both intact protein and subunit level analysis. This
effect proved to be more pronounced in HILIC analysis, indicating
the importance of the strong acidic nature (e.g., MSA and TClAA) of
the additives as ion-pairing reagent to prevent unwanted ionic
interactions on the HILIC stationary phase material.
In RPLC conditions, MSA, TClAA, DClAA and DFA provided
comparable chromatographic behaviour as TFA and therefore could
be considered as valuable alternatives. For HILIC analysis, only
TClAA could replace the chromatographic behaviour of TFA due to
detrimental effects of MSA on the HILIC stationary phase material
leading to a rapid loss of retention. Moreover, in the additive
assessment using LT-ELSD it was observed that 0.1% MSA was not
suitable for use with MS detection due to its limited volatility.
Subsequent evaluation of the MS performance of the remaining
additives showed that the use of TClAA resulted in a substantial loss
of sensitivity in both RPLC and HILIC mode. Therefore, when per-
forming HILIC-MS analysis, the use of TFA is inevitable and
improvement of the MS sensitivity should be realized with other
solutions (e.g., mixed additive usage). For RPLC-MS analysis, a
valuable alternative was found in DFA that provided comparable
chromatographic performance and an improved MS sensitivity.bunits calculated in RPLC (A) and HILIC (B) mode when using selected mobile phase
tate of the subunits associated m/z spectra expressed in counts per seconds (cps). (For
Web version of this article.)
Fig. 8. Middle-up RPLC-MS analysis of trastuzumab by using representative mobile phase additives, namely 1% FA (A) and 0.1% TClAA (B). Total ion chromatograms (i) and
associated m/z spectra of sFc (ii), LC (iii) and Fd (iv) fragments. Cps stands for counts per second.
Fig. 9. Middle-up HILIC-MS analysis of trastuzumab by using 0.1% TFA (A) or 0.1% TClAA (B) as mobile phase additive. Total ion chromatograms (i) and associated m/z spectra of Fd
(ii), LC (iii) and sFc (iv) fragments. For sake of simplicity, only the m/z spectra of the sFc subunit bearing the G0F glycan is shown. Cps stands for counts per second.
H. Lardeux, B.L. Duivelshof, O. Colas et al. Analytica Chimica Acta 1156 (2021) 338347To conclude, this study showed that at chromatographic level
multiple alternatives for TFA are available for both RPLC and HILIC
conditions. By providing equivalent chromatographic behaviour,12they could be used to complement the analysis strategy. However,
the hyphenation to MS requires judicious additive selection by
taking into account the required selectivity and MS sensitivity for
H. Lardeux, B.L. Duivelshof, O. Colas et al. Analytica Chimica Acta 1156 (2021) 338347analysing the therapeutic protein of interest.
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